Objective To investigate the clinical effect of Nuan'gong decoction in the treatment of cold coagulation and blood stasis type menorrhagia.Methods A total of 120 patients with oligomenorrhea were selected and divided into two groups according to random number table method:estrogen and progesterone group and Nuan'gong decoction.The estrogen and progesterone group was treated with se-quential estrogen and progesterone therapy,while the Nuan'gong decoction group was treated with Nuan'gong decoction on the top of the estrogen and progesterone group.The therapeutic effects,menstrual status,and changes in uterine artery blood flow were compared be-tween the two groups.Results The total effective rate of the Nuan'gong decoction group was 91.67％,which was greatly higher than the 76.67％of the estrogen and progesterone group(P＜0.05).After treatment,the traditional Chinese medicine syndrome score and men-strual distress questionnaire(MDQ)Chinese version score of the Nuan'gong decoction group were lower than those of the estrogen and progesterone group(P＜0.05).After treatment,the duration of menstruation in the Nuan'gong decoction group was longer than that in the estrogen and progesterone group(P＜0.05),and the pictorial blood loss assessment chart(PBAC)score was higher than that in the estrogen and progesterone group(P＜0.05).After treatment,the levels of progesterone(P),estradiol(E2),luteinizing hormone(LH),and follicle stimulating hormone(FSH)in the Nuan'gong decoction group were higher than those in the estrogen and progesterone group(P＜0.05).After treatment,the uterine artery pulsatility index(PI),resistance index(BI)and systolic/diastolic peak flow ve-locity(S/D)in the Nuan'gong decoction group were lower than those in the estrogen and progesterone group.Conclusion For patients with cold coagulation and blood stasis type oligomenorrhea,Nuan'gong decoction for traditional Chinese medicine syndrome differentiation treatment can achieve great therapeutic effects,effectively prolong the duration of menstruation,restore menstrual flow and sex hormone levels,and improve the blood flow parameters of uterine artery.

AIM To study the chemical constituents from Periploca forrestii Schltr and their antitumor activity in vitro.METHODS Silica gel and Sephadex LH-20 were used for isolation and purification,then the structures of obtained compounds were identified by physicochemical properties and spectral data.The in vitro antitumor activity was evaluated by MTT mothod.RESULTS Twenty-four compounds were isolated and identified as lysidicichin(1),fraxidin(2),methoxylatifolone(3),corilagin(4),ligballinol(5),6-dehydroprogesterone(6),anomallenodiol(7),mustakone(8),eupatoricacid(9),honokiol(10),methyl 4-hydroxybenzoate(11),5,6,7,8-tetramethoxycoumarin(12),6,7-dimethoxycoumarin(13),5,6,7,4'-tetramethoxyflavone(14),2,3,2",3"-tetrahydrospirotaxone(15),sequoiavone(16),isocubebin(17),isoquercitrin(18),mellein(19),pistaciamide(20),suberoyltrigone(21)、daucosterol(22)、berchemol(23)、confluentin(24).The IC50 value of compound 18 for lung cancer cell NCI-H596 was(27.41±3.36)μmol/L.CONCLUSION Compounds 1-24 are isolated from P.forrestii for the first time.Compound 18 has good antitumor activity in vitro.

Objective To investigate the clinical effect of Nuan'gong decoction in the treatment of cold coagulation and blood stasis type menorrhagia.Methods A total of 120 patients with oligomenorrhea were selected and divided into two groups according to random number table method:estrogen and progesterone group and Nuan'gong decoction.The estrogen and progesterone group was treated with se-quential estrogen and progesterone therapy,while the Nuan'gong decoction group was treated with Nuan'gong decoction on the top of the estrogen and progesterone group.The therapeutic effects,menstrual status,and changes in uterine artery blood flow were compared be-tween the two groups.Results The total effective rate of the Nuan'gong decoction group was 91.67％,which was greatly higher than the 76.67％of the estrogen and progesterone group(P＜0.05).After treatment,the traditional Chinese medicine syndrome score and men-strual distress questionnaire(MDQ)Chinese version score of the Nuan'gong decoction group were lower than those of the estrogen and progesterone group(P＜0.05).After treatment,the duration of menstruation in the Nuan'gong decoction group was longer than that in the estrogen and progesterone group(P＜0.05),and the pictorial blood loss assessment chart(PBAC)score was higher than that in the estrogen and progesterone group(P＜0.05).After treatment,the levels of progesterone(P),estradiol(E2),luteinizing hormone(LH),and follicle stimulating hormone(FSH)in the Nuan'gong decoction group were higher than those in the estrogen and progesterone group(P＜0.05).After treatment,the uterine artery pulsatility index(PI),resistance index(BI)and systolic/diastolic peak flow ve-locity(S/D)in the Nuan'gong decoction group were lower than those in the estrogen and progesterone group.Conclusion For patients with cold coagulation and blood stasis type oligomenorrhea,Nuan'gong decoction for traditional Chinese medicine syndrome differentiation treatment can achieve great therapeutic effects,effectively prolong the duration of menstruation,restore menstrual flow and sex hormone levels,and improve the blood flow parameters of uterine artery.

Lysine-specific demethylase 1(LSD1),a member of the flavin-dependent amine oxidase fam-ily,is a crucial"eraser"of lysine methylation.It reversibly removes methyl groups from histone H3K4me1/2 and H3K9me1/2,thereby regulating gene expression and chromatin function.Located with-in the nucleus,LSD 1 influences various biological processes in tumors,including proliferation,invasion,and metastasis.Previous studies have demonstrated that LSD1 is significantly overexpressed in gynecolog-ical cancers such as ovarian cancer,cervical cancer,and endometrial cancer,and its overexpression is closely associated with poor patient survival and unfavorable prognosis.Research indicates that LSD1 may promote tumor cell proliferation,invasion,and metastasis through the PI3K/AKT and mTOR signaling pathways,while also suppressing tumor cell autophagy and immune surveillance,contributing to immune evasion.In cervical cancer,LSD1 interacts with HPV16 E7,facilitating the epithelial-mesenchymal tran-sition(EMT)process.Furthermore,LSD1 inhibitors have shown promising therapeutic potential in ani-mal studies,particularly in restoring the sensitivity of ovarian cancer cells to platinum-based chemothera-py.This review summarizes the molecular mechanisms,functional targets,and associated signaling path-ways of LSD1 in gynecological cancers,as well as the mechanisms of action of various LSD1 inhibitors,aiming to provide new insights for targeted therapies in gynecological malignancies.

Lysine-specific demethylase 1(LSD1),a member of the flavin-dependent amine oxidase fam-ily,is a crucial"eraser"of lysine methylation.It reversibly removes methyl groups from histone H3K4me1/2 and H3K9me1/2,thereby regulating gene expression and chromatin function.Located with-in the nucleus,LSD 1 influences various biological processes in tumors,including proliferation,invasion,and metastasis.Previous studies have demonstrated that LSD1 is significantly overexpressed in gynecolog-ical cancers such as ovarian cancer,cervical cancer,and endometrial cancer,and its overexpression is closely associated with poor patient survival and unfavorable prognosis.Research indicates that LSD1 may promote tumor cell proliferation,invasion,and metastasis through the PI3K/AKT and mTOR signaling pathways,while also suppressing tumor cell autophagy and immune surveillance,contributing to immune evasion.In cervical cancer,LSD1 interacts with HPV16 E7,facilitating the epithelial-mesenchymal tran-sition(EMT)process.Furthermore,LSD1 inhibitors have shown promising therapeutic potential in ani-mal studies,particularly in restoring the sensitivity of ovarian cancer cells to platinum-based chemothera-py.This review summarizes the molecular mechanisms,functional targets,and associated signaling path-ways of LSD1 in gynecological cancers,as well as the mechanisms of action of various LSD1 inhibitors,aiming to provide new insights for targeted therapies in gynecological malignancies.

Body weight abnormalities, including overweight, obesity, and underweight, have become a dual public health challenge in Chinese adults: overweight and obesity lead to a variety of chronic complications, while underweight increases the risks of malnutrition, sarcopenia, and organ dysfunction. To systematically address these issues, multidisciplinary experts in endocrinology, sports science, nutrition, and psychiatry from various regions have held multiple weight management seminars. Based on the latest epidemiological data and clinical evidence, they expanded the guideline to include assessment and intervention strategies for underweight, in addition to the core content of obesity management. This guideline outlines the etiological mechanisms, evaluation methods, and multidimensional management strategies for overweight and obesity, covering key areas such as diagnosis and assessment, medical nutrition therapy, exercise prescription, pharmacological intervention, and psychological support. It is intended to provide a scientific and standardized approach to weight management across the adult population, aiming to curb the rising prevalence of obesity, mitigate complications associated with abnormal body weight, and improve nutritional status and overall quality of life.

OBJECTIVE: To explore the efficacy and safety of Juan Bi Pill (JBP) in treatment of active rheumatoid arthritis (RA). METHODS: From February 2017 to May 2018, 115 participants from 4 centers were randomly divided into JBP group (57 cases) and placebo group (58 cases) in a 1:1 ratio using a random number table method. Participants received a dose of JBP (4 g, twice a day, orally) combined with methotrexate (MTX, 10 mg per week) or placebo (4 g, twice a day, orally) combined with MTX for 12 weeks. Participants were required with follow-up visits at 24 and 48 weeks, attending 7 assessment visits. Participants were undergo disease activity assessment 7 times (at baseline and 2, 4, 8, 12, 24, 48 weeks) and safety assessments 6 times (at baseline and 4, 8, 12, 24, 48 weeks). The primary endpoint was 28-joint Disease Activity Score (DAS28-ESR and DAS28-CRP). The secondary endpoints included American College of Rheumatology (ACR) criteria for 20% and 50% improvement (ACR20/50), Health Assessment Questionnaire Disability Index (HAQ-DI), clinical disease activity index (CDAI), visual analog scale (VAS), Short Form-36 (SF-36) score, Medial Outcomes Study (MOS) sleep scale score, serum erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tender joint count, swollen joint count, and morning stiffness. The adverse reactions were observed during the treatment. RESULTS: After 12 weeks of treatment, DAS28-ESR and DAS28-CRP scores in both groups were lower than before treatment (both P<0.01), while the remission rate of DAS28-ESR and DAS28-CRP and low disease activity of JBP group were higher than those in the placebo group (both P<0.01). JBP demonstrated better efficacy on ACR20 and ACR50 compliance rate at 12 and 48 weeks comparing to placebo (all P<0.05). The CDAI and HAQ-DI score, pain VAS and global VAS change of RA patients and physicians, the serum ESR and CRP levels, and the number of tenderness and swelling joints were lower than before treatment at 4, 8, 12, 24, 48 weeks in both groups (P<0.05 or P<0.01), while the reduction of above indices in the JBP group was more obvious than those in the placebo group at 12 weeks (ESR and CRP, both P<0.05) or at 12 and 48 weeks (all P<0.01). There was no difference in adverse reactions between the 2 groups during treatment (P=0.75). CONCLUSION JBP combined with MTX could effectively reduce disease activity in patients with RA in active stage, reduce the symptoms of arthritis, and improve the quality of life, while ensuring safety, reliability, and fewer adverse effects. (Trial Registration: ClinicalTrials.gov, No. NCT02885597).
Humans ; Arthritis, Rheumatoid/drug therapy* ; Methotrexate/adverse effects* ; Female ; Double-Blind Method ; Male ; Middle Aged ; Treatment Outcome ; Drugs, Chinese Herbal/adverse effects* ; Drug Therapy, Combination ; Adult ; Antirheumatic Agents/adverse effects* ; Aged

Objective:To improve the understanding of the clinical manifestation of immunoglobulin G 4-related disease (IgG 4-RD) with neurological involvement. Methods:Patients presenting with neurological symptoms and biopsy-confirmed IgG 4-RD were enrolled between March 2014 and March 2024 from the Department of Neurology of Xuanwu Hospital of Capital Medical University. Medical record data of all patients were retrospectively reviewed, including clinical manifestations, laboratory findings, radiological results, pathology, treatments, and outcomes. RD were enrolled between March Results:Nine patients (five males, four females; median age at onset: 63 years) were included in the study. Neurological manifestations consisted of pachymeningitis in six cases, peripheral nerve involvement in two, and brain parenchyma involvement in one. Four patients displayed isolated neurologic symptoms. The most common clinical manifestations were headache and cranial nerve palsy, each involving five cases. Magnetic resonance imaging showed thickening and enhancement of the dura mater in the six patients with pachymeningitis. Four of these cases involved the posterior cranial fossa, 3 presented with an inflammatory pseudotumor, and 2 involved the spinal cord. Four patients with pachymeningitis had normal serum IgG 4 concentrations. Eight patients exhibited elevated serum C-reactive protein or erythrocyte sedimentation rates, with some also showing decreased complement C3 and C4 levels. Cerebrospinal fluid immunoglobulin was elevated in all nine cases. In all cases, histopathologic biopsy results showed extensive infiltration of lymphocytes and plasma cells, with the latter displaying IgG 4+abnormalities. All patients received glucocorticoid therapy, with six also receiving immunosuppressants. All patients were followed up for a median of 30 months, with outcomes including two complete remissions, five partial remissions, one unchanged condition, and one death. Six patients experienced a relapse. Conclusions:Isolated hypertrophic pachymeningitis is the most common manifestation of IgG 4-RD, often occurring in the absence of elevated serum IgG 4 levels. Peripheral nerve and brain parenchyma involvement can also be seen. Clinical manifestations are non-specific, and histopathologic biopsy is frequently required for diagnosis. Although the disease responds well to hormone treatment, recurrence is common. Early combined immunosuppressive therapy can improve prognosis.

AIM To study the chemical constituents from Periploca forrestii Schltr and their antitumor activity in vitro.METHODS Silica gel and Sephadex LH-20 were used for isolation and purification,then the structures of obtained compounds were identified by physicochemical properties and spectral data.The in vitro antitumor activity was evaluated by MTT mothod.RESULTS Twenty-four compounds were isolated and identified as lysidicichin(1),fraxidin(2),methoxylatifolone(3),corilagin(4),ligballinol(5),6-dehydroprogesterone(6),anomallenodiol(7),mustakone(8),eupatoricacid(9),honokiol(10),methyl 4-hydroxybenzoate(11),5,6,7,8-tetramethoxycoumarin(12),6,7-dimethoxycoumarin(13),5,6,7,4'-tetramethoxyflavone(14),2,3,2",3"-tetrahydrospirotaxone(15),sequoiavone(16),isocubebin(17),isoquercitrin(18),mellein(19),pistaciamide(20),suberoyltrigone(21)、daucosterol(22)、berchemol(23)、confluentin(24).The IC50 value of compound 18 for lung cancer cell NCI-H596 was(27.41±3.36)μmol/L.CONCLUSION Compounds 1-24 are isolated from P.forrestii for the first time.Compound 18 has good antitumor activity in vitro.

OBJECTIVE: This study aimed to reexplore minimum iodine excretion and to build a dietary iodine recommendation for Chinese adults using the obligatory iodine loss hypothesis. METHODS: Data from 171 Chinese adults (19-21 years old) were collected and analyzed based on three balance studies in Shenzhen, Yinchuan, and Changzhi. The single exponential equation was accordingly used to simulate the trajectory of 24 h urinary iodine excretion as the low iodine experimental diets offered (iodine intake: 11-26 μg/day) and to further deduce the dietary reference intakes (DRIs) for iodine, including estimated average requirement (EAR) and recommended nutrient intake (RNI). RESULTS: The minimum iodine excretion was estimated as 57, 58, and 51 μg/day in three balance studies, respectively. Moreover, it was further suggested as 57, 58, and 51 μg/day for iodine EAR, and 80, 81, and 71 μg/day for iodine RNI or expressed as 1.42, 1.41, and 1.20 μg/(day·kg) of body weight. CONCLUSION The iodine DRIs for Chinese adults were established based on the obligatory iodine loss hypothesis, which provides scientific support for the amendment of nutrient requirements.
Humans ; Iodine/administration & dosage* ; Male ; Female ; China ; Young Adult ; Diet ; Adult ; Nutritional Requirements ; East Asian People